Adar Poonawalla’s super lucky turn
A look inside the very risky bet that has suddenly made the Serum Institute CEO Indian healthcare’s new, controversial poster boy.
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
$99 for one year
Not ready to subscribe? Sign up for a free account
We value our free readers. Read 100+ stories every year.
More in Business
You may also like
News explainers that stood out in 2024
Bluesky vs X, the UAE deluge, Adar Poonawalla’s investment in Karan Johar’s Dharma Productions and more.
How Bewakoof, once a trendsetter, fell out of favour with young people
Indian youngsters are experimenting with newer D2C brands like never before. Bewakoof’s early success and its 2022 acquisition by retail giant Aditya Birla Fashion should have given it the edge, but the company has been left behind.
Why is Swiggy catching flak for its latest quick-delivery promise?
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
